Two scientific symposia were conducted on the 2nd October 2019 and 29th October 2019. Multiple international faculty members shared their perspectives and experiences of using NeuroAiDTM in stroke management from different clinical settings.
- Professor Jose C. Navarro from University Santo Tomas Hospital, Philippines, moderated the scientific sessions during APSC
- Professor Christopher Chen from the National University of Singapore, presented the effects of NeuroAiDTM on long-term functional outcomes after stroke
- Professor Nijasri C. Suwanwela from Chulalongkorn University Thailand, presented the effects of combination treatment with NeuroAiDTM and rehabilitation
- Professor Anita Arsovska from University Clinical of Neurology, University Ss Cyril and Methodius from North Macedonia, presented sustaining post-stroke recovery with NeuroAiDTM
- Professor Ihsan K. Al-Shimmery from Iraq, presented Bridging Stroke Updates to Clinical Experience
- Professor Mitchel Lazdunski from CNRS France, presented NeuroAiDTM’s multimodal mode of action
Professor Chen commented that “it is spectacular that even a 3-month treatment can (translate to) such long-term benefit, and highlighted that “in patients who do not have such a good prognosis, NeuroAiDTM enhances recovery and more patients gradually improved to full independence (mRS 0 – 1) and they stayed there”. After presenting a series of interventions that are useful to encourage neuroplasticity, Professor Nijasri highlighted that “maybe we need a combination of the treatments, not only physiotherapy but maybe some other ways to enhance recovery”. Both Professor Anita and Professor Ihsan acknowledged the efficacy of NeuroAiD among the majority of their clinical settings, with well-tolerated safety profile. Using the results of a recent study, he presented that NeuroAiD™ is able to regulate neuroinflammation, which is essential to initiate and maintain the process of neuro-repair after brain injuries.
CHIMES-E, NeuroAiD’s landmark study, assessed recovery for up to 2 years following a stroke. More patients in the treatment group achieved functional independence (mRS 0-1) with significant results from month 6 to 18 compared to the placebo group. Moreover, combining NeuroAiD and rehabilitation doubled the odds of achieving functional independence as early as month-3, with the effect persisting over 2 years as compared to patients who underwent rehabilitation alone.
NeuroAiD (either MLC 601 or MLC 901), as first known as a Traditional Chinese Medicine, is a natural product combining several active ingredients including nine herbal extracts in the form of capsules. NeuroAiD properties have been studied extensively in post-stroke recovery and the research is widely published. Since its first commercialization in 2006, NeuroAiD™ has shown a rapid and stable growth internationally, and is available today in numerous countries of several regions (South East Asia, Europe, Middle East, and Africa). Pharmacology research has established the neuroprotective and neurorestorative activities of NeuroAiD providing possible mechanisms for neurological recovery in post-stroke survivors.
Moleac is a pharmaceutical company headquartered in Singapore and focused on developing and commercializing treatment for the patients suffering a loss of brain functions after brain injuries or neurodegenerative diseases. Moleac was founded by French entrepreneurs and scientists in 2002 and is headquartered in Singapore.